NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 7, 2021

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma

Interventions

OTHER

Hafnium Oxide-containing Nanoparticles NBTXR3

Given intratumorally/intranodally

RADIATION

Hypofractionated Radiation Therapy

Undergo hypofractionated RT

BIOLOGICAL

Pembrolizumab

Given IV

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER